Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia

Exclusion Criteria

• •VT in the setting of metabolic abnormalities or acute ischemia if coronary lesions suitable for revascularization are identified.
• •Acute ischemia with eligibility for revascularization
• •Significant peripheral arterial disease preventing transvascular access to the left ventricle.
• •Patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy, Brugada syndrome, Long QT syndromes, dilated cardiomyopathy
• •Prior long term therapy with a Class III or Class IC antiarrhythmic agent (longer than 2 weeks)
• •Patient is or may be potentially pregnant
• •Patient has a mechanical heart valve
• •Myocardial infarction within the past 90 days
• •Stroke within the past 90 days
• •New York Heart Association (NYHA) functional class IV
• •Hemorrhagic manifestations, bleeding diathesis, or impairment of hemostasis
• •Lesions at risk of clinically significant bleeding (e.g., extensive cerebral infarction within the last 6 months, active peptic ulcer disease with recent bleeding)
• •Prior VT ablation procedure
• •Contraindication or allergy to contrast media, routine procedural medications or catheter materials
• •Contraindications to an interventional procedure
• •Life expectancy is less than 6 months
• •Incessant or multiple episodes of VT requiring immediate therapy with medications or ablation
• •Untreated hypothyroidism or hyperthyroidism (euthyroid or thyroid hrt is acceptable)
• •Current enrolment in another investigational drug or device study
• •There are other conditions present that the investigator feels would be problematic or would restrict or limit the participation for the patient for the entire study period
• •Absolute contraindication to the use of heparin or warfarin
• •Documented intra-arterial thrombus, ventricular thrombus, (less than 6 months after detection of thrombus), tumor or other abnormality that precludes catheter introduction